Peter Pang

Peter Pang focuses on capital markets, private equity and cross-border mergers and acquisitions.

Highlights from Mr. Pang’s experience include representing:

Capital Markets

• AMTD International Inc. in its US$200 million U.S. IPO and NYSE listing;
• NIO Inc. in its US$1 billion U.S. IPO and NYSE listing;
• the underwriters in the US$101 million U.S. IPO of Four Seasons Education (Cayman) Inc.;
• China Renaissance Holdings Limited in its US$350 million Hong Kong IPO;
• VCREDIT Holdings Limited in its US$163 million Hong Kong IPO;
• Yixin Group Limited in its US$870 million Hong Kong IPO;
• Baidu, Inc. in its US$1.25 billion SEC-registered investment-grade note offerings;
• Bitauto Holdings Limited in its US$150 million private placement of convertible notes;
• Ctrip.com International, Ltd. in its US$2.6 billion concurrent SEC-registered follow-on ADS offering and Rule 144A/Regulation S offerings of convertible notes and ordinary shares;
• Weibo Corporation in its US$800 million SEC-registered investment-grade note offering;
• YY Inc. in its US$463 million SEC-registered follow-on ADS offering; and
• AMTD International Inc., Ctrip.com International, Ltd., NIO Inc. and Vipshop Holdings Limited in their U.S. securities law compliance, corporate governance and periodic reporting.

M&A and Private Equity

• Capital Group Private Markets in its investment with GL Capital for approximately 29 percent stake in JINXIN Medical Investment Group Limited in June 2018;
• NIO Inc. in its Series D preferred share financing in November 2017;
• Ctrip.com International, Ltd. in its £1.4 billion acquisition of UK-based Skyscanner Holdings Limited through cross-border tender offer; US$213 million convertible notes investments in MakeMyTrip Limited; and in its US$1 billion convertible notes investments by The Priceline Group Inc. and Hillhouse Capital;
• National Silicon Industry Group in its €170 million takeover of Okmetic Oyj through a voluntary public tender offer in November 2016;
• Tencent Holdings Limited in its US$69 million acquisition, as part of an investor group including Huayi Brothers and other investors, of a 51 percent interest in China Jiuhao Health Industry Corporation; and
• The Carlyle Group in its US$64 million investment for a 15.7 percent stake in Zhongmei Healthcare Group Limited in January 2016.